Adipose-derived stromal vascular fraction (SVF) cell populations are being evaluated for numerous clinical applications. The current study evaluated a point-of-care technology, the Tissue Genesis "TGI 1000" Cell Isolation Systemâ„¢, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. A total of seven patients were enrolled in this study and received femoral to tibial expanded polytetrafluoroethylene bypass grafts to treat peripheral arterial disease.
View Article and Find Full Text PDFWe evaluated the use of an automated, point-of-care instrument to derive canine adipose stromal vascular fraction cells, and the subsequent deposition of these cells onto the luminal surface of an expanded polytetrafluoroethylene (ePTFE) vascular graft for use as a bypass graft. The hypothesis evaluated was that an instrument requiring minimal user interface will provide a therapeutic dose of cells to improve the patency of synthetic vascular grafts in an autologous animal model of graft patency. The stromal vascular fraction (SVF) cells were isolated using an automated adipose tissue processing and cell isolation system and cells sodded onto the surface of an ePTFE vascular graft.
View Article and Find Full Text PDFDevelopment of a small diameter (<6 mm) synthetic vascular graft with clinically acceptable patency must overcome the inherent thrombogenicity of polymers and the development of neointimal thickening. Establishment of an endothelial cell lining on the lumenal surface has been hypothesized as a mechanism to improve the function of vascular grafts. The major aim of this study is to evaluate the use of laminin type 1, covalently bound to all surfaces of expanded polytetrafluoroethylene (ePTFE) grafts, on neovascularization of the interstices and lumenal surface endothelialization.
View Article and Find Full Text PDFPurpose: Use the ID(50) (infectious dose to 50% of experimental animals) to quantify the most effective prophylactic dosing regimen to use with gatifloxacin 0.3% (Zymar) for the prevention of keratitis in a rabbit laser in situ keratomileusis model of Staphylococcus epidermidis infection.
Setting: University Laboratory, University of Arizona, Tucson, Arizona, USA.
Healing associated with many polymeric biomedical implants commonly involves the formation of an avascular fibrous capsule. The lack of either formation or persistence of blood vessels in formed fibrous capsules, as well as a lack of new blood vessels within porous polymeric implants, often results in poor performance of the implant. The current study evaluated the use of extracellular matrix protein modification of a commonly used biomedical implant material, expanded polytetrafluoroethylene (ePTFE), as a mechanism to increase the neovascularization both within these porous implants and in tissue that forms in the peri-implant area.
View Article and Find Full Text PDFBackground: A variety of nondegradable polymers have been evaluated for use as soft-tissue augmentation devices. This study compared a novel dual porosity expanded polytetrafluoroethylene with current, clinically used devices.
Methods: Studies were performed in a porcine model of soft-tissue healing with both histologic evaluations and determination of biomechanical strength of tissue incorporation.
The response of epicardial tissue to the implantation of expanded polytetrafluoroethylene (ePTFE) was evaluated and compared with identical material implanted within subcutaneous and adipose tissues. These two tissue environments were selected for comparison with epicardial implants because they represent tissue often involved in device implantation. Discs of ePTFE (6 mm) were implanted into three different tissue sites in Sprague-Dawley rats.
View Article and Find Full Text PDF